Although cancer in children is rare, it is the No. 1 cause of death from disease among children in the United States. There are many types of childhood cancer, each requiring various treatments or combinations of treatments. Through the combined efforts of pediatric cancer specialists and extensive research in the field, real advances have been made in the treatment of childhood cancer. However, much remains to be accomplished and you can be a part of this effort.
The Mississippi Children's Cancer Center at Batson Children's Hospital is the only center in the state providing comprehensive care for children with cancer or blood-related diseases. Completed in 1991 and made possible by the fundraising efforts of the Junior League of Jackson, the center is designed to provide outpatient care needs for children with cancer, sickle cell and other blood diseases.
The 17,750 square-foot facility includes patient care areas and laboratory research facilities. There are eight examining rooms, two treatment rooms, a chemotherapy administration room, and a large, comfortable chemotherapy observation room lined with windows affording patients a view outside. There are separate waiting room and play areas, where volunteers can play with the children and interact with families.
At the Mississippi Children's Cancer Center, we have cared for more than 1,500 children with cancer. Currently, we follow approximately 800 children with cancer, including those receiving therapy and those being monitored after completing therapy.
Our mission at the Mississippi Children's Cancer Center is to improve children's health through scientific discoveries attainable by conducting cutting edge research and translating the discoveries into clinical care.
Our multidisciplinary Pediatric Oncology Clinical and Translational Research team is led by Dr. Gail Megason, director of the Children's Cancer Center, and professor and executive vice chair of Pediatrics. The creation of our multidisciplinary collaborative research team was motivated by the realization that team science and completely new strategies are needed if we are to develop novel curative therapies and early interventions for all childhood cancers. We hope to rapidly develop more precise and effective treatments based on the unique characteristics of each child's tumor and genomic make up. Our research team has deep expertise in the most lethal pediatric cancers, and are combining their experience and commitment to a sustained effort to improve cure rates.
Our team applauds each of the patients who step forward to participate in research and clinical trials. Without patients who generously commit their time to participate in research and clinical trials, scientific advances would grind to a halt and development of novel therapeutic strategies would be inconceivable.